News 20.11.2023 Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading...
Events, Internal events
Event date: 05.12.2023
When: Tuesday, December 5th, at 16:00h.
Where: Seminar room L121/123, Wagistrasse 12, 6th floor
Presenter: Sebastian Kobold, Ludwig-Maximilians-Universität München, Germany
Sebastian Kobold, M.D. is a professor of experimental immunooncology, head of the immunopharmacology group, and deputy director of the division of clinical pharmacology at the University Hospital of Munich. He has received, among...
News 14.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present on several of its programs at the 15th Annual Protein & Antibody Engineering European...
Events, Internal events
Event date: 07.12.2023
Date and time: Thu, Dec 7, 2023 11:30 AM - 12:30 PM CET
Location: Dinaqor - Conference Room, Wagistrasse 25, 8952 Schlieren
Rapid Novor is at the forefront of accelerating therapeutic antibody discovery with our cutting-edge REpAb® platform. Based in Canada, our expertise lies in de novo protein sequencing, advancing the capabilities...
News 07.11.2023 Switzerland, 07 November – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the successful completion of patient recruitment for the Phase 2 clinical trial of its lead product, denovoSkin™, in reconstructive surgery for both children and adults. This Phase 2 clinical trial...